This implies that future combination therapeutic regimens involving recombinant Apo2L/TRAIL and standard chemotherapeutic drugs for the treatment of osteosarcoma and other cancer types, may not only provide a more effective treatment, but would also require lower doses of drugs than those currently used. Here, TNFSF10 is linked to cancer.